The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T
Abstract
OBJECTIVE: To determine whether glutamate + glutamine (GLX) levels in the brain as measured in vivo with proton MRS at 0.5 tesla (T) distinguish between probable Alzheimer's disease and normal aging. BACKGROUND: Glutamatergic markers had been measured previously in postmortem brain tissue. Conventional proton MRS at 1.5 T cannot reliably detect the GLX resonance in vivo. The authors developed a technique at 0.5 T that is sensitive to the GLX resonance. METHODS: Metabolite ratios using creatine and phosphocreatine resonance as an internal standard were acquired from the cingulate region of 18 patients with AD and 12 healthy controls. The major resonances in the spectrum were examined: N-acetylaspartate (NAA), choline-containing compounds, myo-inositol, and GLX. The Mini-Mental State Examination (MMSE) was used to assess cognitive status. The Instrumental Activities of Daily Living Scale (Instrumental ADL) was used to assess functional status. RESULTS: Reduced ratios of GLX (-10%, p = 0.001) and NAA (-12%, p = 0.000) were found in patients with AD. Increased ratios of myo-inositol in patients with AD approached significance (+14%). GLX ratios of patients with AD were correlated with MMSE (r = 0.61, p = 0.007) and Instrumental ADL (r = 0.59, p = 0.01) scores. The combined sensitivity of NAA and myo-inositol in correctly diagnosing AD was 78%. The addition of GLX to NAA and myo-inositol increased the sensitivity to 89%. Overall diagnostic accuracy improved from 80 to 83% with the addition of GLX. CONCLUSIONS: Glutamate + glutamine reduction may be a biologic marker for AD and may be a potential aid in the early clinical diagnosis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concentrations of Glu were also shown to be lower in the posterior cingulate cortex of AD patients, either when measured alone or as a combined measure of Glu+glutamine (Glx) (Antuono et al. 2001; Fayed et al. 2011; Rupsingh et al. 2011).”
From Alzheimer’s disease: Targeting the glutamatergic system (2020) · cites this paper as Antuono et al. 2001
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Vogt, B. A., Finch, D. M., & Olson, C. R. (1992) · Cerebral Cortex · doi:10.1093/cercor/2.6.435-a · Cited by 1,315
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 961
Multinuclear NMR Studies on the Energy Metabolism of Glial and Neuronal Cells
Brand, A., Richter‐Landsberg, C., & Leibfritz, D. (1994) · Developmental Neuroscience · doi:10.1159/000111347 · Cited by 889
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991) · Science · doi:10.1126/science.1835799 · Cited by 841
Research works printed but not linked: 2
- Hugon J Vallat JM, Dumas M. Role of glutamate and excitotoxicity in neurologic diseases. Rev Neurol (Paris) . 1996; 152: 239–248.
- Braak H, Griffing K, Braak E. Neuroanatomy of Alzheimer’s disease. Alzheimer Res . 1997; 3: 235–247.
Cited by
Sorted by citations
The Glutamatergic System and Alzheimer???s Disease
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 274
On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey
Alberdi, A., Aztiria, A., & Basarab, A. (2016) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2016.06.003 · Cited by 231
Reduced hippocampal glutamate in Alzheimer disease
Rupsingh, R., Borrie, M., Smith, M., Wells, J. L., & Bartha, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.002 · Cited by 177
Alzheimer’s disease: Targeting the glutamatergic system
Conway, M. E. (2020) · Biogerontology · doi:10.1007/s10522-020-09860-4 · Cited by 180
Kashani, A., Lepicard, E. M., Poirel, O., Videau, C., David, J. P., Fallet‐Bianco, C., Simon, A., Delacourte, A., Giros, B., Epelbaum, J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.010 · Cited by 186
Metadata
- Authors
- Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J.
- Affiliations
- Medical College of Wisconsin (US)
- ORCID
- Jones, Jennifer L.
- Venue
- Neurology
- Published
- 2001-03-27
- Volume
- 56
- Issue
- 6
- Pages
- 737-742
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2101563929
- Cited by
- 119
- References
- 42
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 5 · 2012: 6
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (5M01-RR00058, M01RR000058)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, glutamate/glutamine, 1H NMR, 0.5T MRI, N-acetylaspartate, myo-inositol, brain metabolites, diagnostic biomarkers, early diagnosis, normal aging, cingulate cortex
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Glutamine, Humans, Male, Middle Aged, Magnetic Resonance Spectroscopy, Protons, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
